Loading organizations...
ElevateBio is a Waltham, Massachusetts-based cell and gene therapy foundry and holding company that combines centralized manufacturing capabilities, technology platforms, and therapeutic development services. The organization operates a portfolio of specialized biotechnology firms while simultaneously providing contract manufacturing and process development expertise to external biopharmaceutical partners ranging from early-stage startups to multinational corporations. Its broader ecosystem includes long-term strategic partnerships with medical centers like Massachusetts General Hospital, alongside a portfolio of affiliated therapeutics companies such as AlloVir, HighPassBio, and LifeEdit Therapeutics. To support its dedicated manufacturing infrastructure and advance its internal clinical pipeline, the enterprise has secured substantial venture capital funding across multiple tranches, including a $150 million Series A, a $170 million Series B, and an additional $525 million financing round. ElevateBio was founded in 2017 by David Hallal, Mitchell Finer, and Vikas Sinha.
ElevateBio has raised $1.3B across 4 funding rounds.
Key people at ElevateBio.
ElevateBio was founded in 2017 by David Hallal (CEO, Chair, & Co-Founder).
ElevateBio has raised $1.3B in total across 4 funding rounds.
ElevateBio has raised $1.3B across 4 funding rounds. Most recently, it raised $400.0M Series D in May 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 1, 2021 | Abata Therapeutics | $95.0M Series A | Third Rock Ventures | Invus, JDRF, Lightspeed Venture Partners, Samsara BioCapital |
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2023 | $400M Series D | Ayurmaya, Matrix Capital Management | MPM Capital, RA Capital, EcoR1 Capital, EDBI, Emerson Collective, F2 Ventures, Fidelity Management & Research Company, Khalil Barrage, LEE Family Office, Karina Thorn, R&D Partner, Redmile Group, Samsara BioCapital, Softbank, Surveyor Capital, Vertex Ventures, Woodline Partners | Announced |
| Mar 1, 2021 | $530M Series C | — | Stuart Peterson, Cisco Investments, DFJ, Kevin Ding, Felicis Ventures, Foundation Capital, General Catalyst, Madrona Venture Group, Next47, Sequoia Capital, Wing Venture Capital, Fidelity Management & Research Company, Karan Takhar, Deep Nishar | Announced |
| Mar 30, 2020 | $170M Series B | — | EcoR1 Capital, Swee Yeok Chu, PBM, F2 Ventures, Invus, MPM Capital, Redmile Group, Samsara BioCapital, Surveyor Capital, Vertex Ventures | Announced |
| May 13, 2019 | $150M Series A | Morana Jovan Embiricos, Ansbert Gadicke | Oleg Nodelman, Redmile Group, Samsara BioCapital | Announced |
Key people at ElevateBio.
ElevateBio is a technology-driven biotechnology company that powers the development and manufacturing of transformative cell and gene therapies, known as genetic medicines.[1][2][4] It builds an integrated ecosystem combining R&D platforms like Life Edit—a next-generation gene editing toolbox—and BaseCamp, its end-to-end cGMP manufacturing and process development business, to accelerate therapies from concept to commercialization for partners targeting diseases such as cancer, genetic disorders, and infectious conditions.[1][2][3][4] Serving biopharma companies and internal programs, ElevateBio solves key bottlenecks in the industry by de-risking development through unified technologies (e.g., ex vivo/in vivo therapies, viral/non-viral delivery, lipid nanoparticles), cutting-edge manufacturing, and AI-driven insights, enabling faster delivery of potentially curative treatments.[2][3][5][7]
ElevateBio was founded over seven years ago (around 2018 or earlier) to redefine genetic medicine development beyond traditional biotech or contract manufacturing models, creating a "genetic medicine foundry" with fully integrated tech stacks and end-to-end capabilities.[3][6] Key figures include industry-leading experts in gene editing, cellular engineering, and manufacturing, though specific founders are not detailed in available sources; the company has assembled top talent with hands-on experience in cell/gene therapy discovery and production.[2][6][8] Early traction came from building world-class facilities, diverse platforms (e.g., gene editing, iPSCs, protein/viral engineering), and BaseCamp as a centralized hub, positioning it to bridge discovery gaps and support rapid innovation amid rising demand for scalable therapies.[3][6]
ElevateBio stands out through its foundry model, the first fully integrated stack combining R&D technologies and manufacturing:
ElevateBio rides the explosive growth of cell and gene therapy, a trend shifting medicine toward curative genetic interventions for untreatable diseases, fueled by CRISPR advancements and manufacturing scalability needs.[1][3][4] Timing is ideal amid regulatory approvals, biopharma investments, and post-pandemic biotech momentum, where traditional models fail on speed and integration—ElevateBio's foundry addresses this "missing link" between discovery and delivery.[2][3] Market forces like enormous data from engineering processes and demands for AI-enabled efficiency favor its data architecture and emerging tech evaluations.[5][7] It influences the ecosystem by partnering with biopharma, de-risking pipelines, and standardizing high-quality manufacturing, potentially making genetic medicines "everyday" therapies.[2][4]
ElevateBio is poised to lead as genetic medicines scale, with expansions in AI-protein engineering, non-viral delivery, and automated systems driving internal pipelines and partnerships toward commercialization.[3][5][8] Trends like multiplex editing for complex disorders, digital manufacturing, and data unification will shape its path, amplifying impact as therapies target broader indications.[7][8] Its influence may evolve into a dominant platform provider, redefining biotech by embedding intelligence across the value chain and powering widespread access to regenerative cures—solidifying its role as the engine for tomorrow's medicine.[1][3]
ElevateBio was founded in 2017 by David Hallal (CEO, Chair, & Co-Founder).
ElevateBio has raised $1.3B in total across 4 funding rounds.
ElevateBio's investors include AyurMaya, Matrix Capital Management, MPM Capital, RA Capital, EcoR1 Capital, EDBI, Emerson Collective, F2 Ventures, Fidelity Management & Research Company, Khalil Barrage, Lee Family Office, Karina Thorn.
